在心力衰竭中使用的-葡萄糖共载体-2 (SGLT-2) 抑制剂:一项综合性审查
Raj Roy1, Saketh Vinjamuri1, Rishabh Baskara Salian2
1Internal Medicine, Gandhi Medical College and Hospital, Secunderabad, IND.
Cureus
|August 21, 2023
概括
-葡萄糖共运输体-2 (SGLT-2) 抑制剂显著减少心力衰竭住院和心血管死亡. 这些SGLT-2抑制剂对于治疗心力衰竭患者安全有效,改善了他们的生活质量.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 心力衰竭是导致死亡和住院的主要原因.
- 尽管有进展,但心力衰竭的管理仍然具有挑战性.
- -葡萄糖共运输体-2 (SGLT-2) 抑制剂是一种新的治疗类.
研究的目的:
- 对心力衰竭SGLT-2抑制剂的元分析进行总体审查.
- 综合关于SGLT-2抑制剂在心力衰竭患者中的有效性和安全性的证据.
- 评估SGLT-2抑制剂对住院治疗,死亡率和生活质量的影响.
主要方法:
- 对元分析的总体综述.
- 搜索了五个数据库:PubMed,Cochrane图书馆,Scopus,全球指数Medicus,科学直接.
- 包括5个以上RCT的元分析;使用AMSTAR评估质量.
主要成果:
- 分析了包括171,556名患者在内的10个元分析.
- SGLT-2 抑制剂显著减少了心力衰竭住院的情况.
- SGLT-2 抑制剂降低了心血管死亡,全因死亡率和严重不良事件.
- 在接受SGLT-2抑制剂治疗的患者中观察到生活质量的改善.
结论:
- SGLT-2 抑制剂在减少心力衰竭中心血管不良结果方面显示出显著的益处.
- 这些发现支持SGLT-2抑制剂在心力衰竭管理中的安全性和有效性.
- SGLT-2 抑制剂代表了一种有价值的治疗选择,可以改善心力衰竭患者的治疗结果.
相关概念视频
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:26Heart Failure Drugs: Inotropic Agents
621
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364